Charles has deep experience in healthcare innovations. He has served as CEO of Aquea Health since the company’s founding.  He has been a Managing Director with Versant Ventures since 2004, and previously was General Partner at SV Life Sciences. He has held numerous board director roles with companies focused on bringing innovative solutions to patients. Charles is presently lead independent director of Ocular Therapeutix (OCUL).

Andy is a serial entrepreneur with a mission to advance health and human life. Currently he is Founder and CEO at Koya Medical, a growth stage venous and lymphatic solution and board director at Rivermark Medical. Previously, he headed Santen’s US surgical intraocular lens business (licensed as enVista IOL to Bausch &; Lomb) and headed operations at Oculeve
(acquired by Allergan).

Dan is an experienced clinical and regulatory executive. Initially with Cooper Surgical and subsequently with Alcon, Dan then led clinical and regulatory affairs with AVS (acquired by Santen) and Oculeve (acquired by Allergan).

Mark brings years of experience as an accomplished surgeon and Key Opinion Leader across all aspects of ophthalmology. He has advised numerous companies on clinical and medical affairs, helping companies navigate from concept through regulatory approval.